Voya Investment Management LLC Has $245,000 Stock Holdings in Iovance Biotherapeutics, Inc. $IOVA

Voya Investment Management LLC lessened its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 56.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 73,719 shares of the biotechnology company’s stock after selling 96,018 shares during the period. Voya Investment Management LLC’s holdings in Iovance Biotherapeutics were worth $245,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Iovance Biotherapeutics by 202.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after purchasing an additional 3,869,617 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Iovance Biotherapeutics by 30.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,571,902 shares of the biotechnology company’s stock worth $18,554,000 after purchasing an additional 1,301,846 shares during the last quarter. Teza Capital Management LLC acquired a new position in shares of Iovance Biotherapeutics during the 1st quarter worth about $51,000. Invenomic Capital Management LP bought a new position in Iovance Biotherapeutics during the first quarter valued at about $18,281,000. Finally, Jacobs Levy Equity Management Inc. bought a new position in Iovance Biotherapeutics during the first quarter valued at about $4,191,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Analyst Ratings Changes

IOVA has been the topic of several research reports. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Iovance Biotherapeutics in a research note on Tuesday, August 19th. Wells Fargo & Company lowered their price target on Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. The Goldman Sachs Group lowered Iovance Biotherapeutics from a “neutral” rating to a “sell” rating in a research note on Tuesday, July 15th. Zacks Research upgraded Iovance Biotherapeutics to a “hold” rating in a research note on Tuesday, August 12th. Finally, Chardan Capital lowered their price target on Iovance Biotherapeutics from $25.00 to $20.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $11.90.

Iovance Biotherapeutics Price Performance

IOVA stock opened at $2.23 on Tuesday. The business has a fifty day moving average price of $2.47 and a 200 day moving average price of $2.51. Iovance Biotherapeutics, Inc. has a fifty-two week low of $1.64 and a fifty-two week high of $12.51. The stock has a market capitalization of $806.93 million, a price-to-earnings ratio of -1.81 and a beta of 0.82.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04). Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. The business had revenue of $59.95 million for the quarter, compared to analyst estimates of $67.14 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. On average, equities analysts expect that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.